Arrowhead Pharmaceuticals reported fiscal 2026 third-quarter results ending June 30, 2026, with revenue of $75.3 million compared to $27.8 million in the prior year period. The company incurred a net loss attributable to shareholders of $194.3 million, or $1.36 per diluted share, against a loss of $175.2 million previously. Cash and available-for-sale securities totaled $1.57 billion at quarter-end. Key developments included the European Commission granting marketing authorization for REDEMPLO (plozasiran) for familial chylomicronemia syndrome and an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, generating a $25 million upfront payment. Additionally, topline results from Phase 3 SHASTA-3 and SHASTA-4 studies demonstrated significant triglyceride reductions for plozasiran in severe hypertriglyceridemia patients.

On June 12, 2026, Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a director. Dr. Cohen brings over 25 years of healthcare investing experience, including roles as Managing Director at Vida Ventures and lead growth-focused healthcare investor at JP Morgan Asset Management. In addition to standard non-employee director compensation, he will receive a sign-on grant of restricted stock units valued at $887,000, vesting over three years. The company is a biotechnology firm that develops RNAi therapeutics.